Vor Biopharma (NASDAQ:VOR) Trading 6.1% Higher – Still a Buy?

Shares of Vor Biopharma Inc. (NASDAQ:VOR) traded up 6.1% during mid-day trading on Tuesday . The stock traded as high as $23.41 and last traded at $23.2250. Approximately 532,604 shares changed hands during mid-day trading, a decline of 49% from the average session volume of 1,048,599 shares. The stock had previously closed at $21.89.

Analysts Set New Price Targets

Several equities research analysts have commented on the stock. Weiss Ratings raised shares of Vor Biopharma from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Monday, September 14th. Wall Street Zen raised Vor Biopharma from a “sell” rating to a “hold” rating in a research report on Saturday, August 15th. Finally, Wedbush upped their target price on Vor Biopharma from $18.00 to $27.00 and gave the stock a “neutral” rating in a report on Wednesday, August 12th. Two investment analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $41.71.

Vor Biopharma Trading Down 12.0%

The business has a fifty day moving average of $22.11 and a 200 day moving average of $17.81.

Vor Biopharma (NASDAQ:VOR) last released its quarterly earnings data on Tuesday, August 11th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.69) by ($0.11). On average, analysts forecast that Vor Biopharma Inc. will post -2.56 EPS for the current fiscal year.

Institutional Investors Weigh In On Vor Biopharma

A number of large investors have recently added to or reduced their stakes in VOR. Engineers Gate Manager LP lifted its holdings in Vor Biopharma by 37.5% during the 2nd quarter. Engineers Gate Manager LP now owns 36,951 shares of the company’s stock valued at $680,000 after purchasing an additional 10,071 shares during the last quarter. Braidwell LP boosted its position in Vor Biopharma by 22.8% during the second quarter. Braidwell LP now owns 573,104 shares of the company’s stock worth $10,551,000 after purchasing an additional 106,330 shares during the period. Wellington Management Group LLP acquired a new position in shares of Vor Biopharma in the second quarter valued at $499,000. Bank of New York Mellon Corp acquired a new position in shares of Vor Biopharma in the second quarter valued at $1,799,000. Finally, Bank of America Corp DE raised its position in shares of Vor Biopharma by 28,408.1% in the first quarter. Bank of America Corp DE now owns 112,892 shares of the company’s stock valued at $2,014,000 after purchasing an additional 112,496 shares during the period. Institutional investors own 97.29% of the company’s stock.

Vor Biopharma Company Profile

Vor Biopharma Inc is a clinical-stage biotechnology company focused on developing treatments for patients with hematologic malignancies, including acute myeloid leukemia (AML). The company combines engineered hematopoietic stem cell therapies with targeted cancer medicines in an effort to improve the selectivity and effectiveness of treatment.

Vor’s lead program, trem-cel (formerly known as VOR33), is an investigational gene-edited hematopoietic stem cell therapy designed to eliminate the CD33 protein from blood-forming stem cells.